Substrate and Substrate-Mimetic Chaperone Binding Sites in Human α-Galactosidase A Revealed by Affinity-Mass Spectrometry.

about

Substrate and Substrate-Mimetic Chaperone Binding Sites in Human α-Galactosidase A Revealed by Affinity-Mass Spectrometry.

Item

http://www.wikidata.org/entity/Q50858691

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Substrate and Substrate-Mimeti ...... by Affinity-Mass Spectrometry.

@en

Substrate and Substrate-Mimeti ...... by Affinity-Mass Spectrometry.

@nl

type

Item

label

Substrate and Substrate-Mimeti ...... by Affinity-Mass Spectrometry.

@en

Substrate and Substrate-Mimeti ...... by Affinity-Mass Spectrometry.

@nl

prefLabel

Substrate and Substrate-Mimeti ...... by Affinity-Mass Spectrometry.

@en

Substrate and Substrate-Mimeti ...... by Affinity-Mass Spectrometry.

@nl

P1476

Substrate and Substrate-Mimeti ...... by Affinity-Mass Spectrometry.

@en

P2093

Adrian Moise

http://www.w3.org/2001/XMLSchema#string

Frederike Eggers

http://www.w3.org/2001/XMLSchema#string

Jeff Bornheim

http://www.w3.org/2001/XMLSchema#string

Mary Murphy

http://www.w3.org/2001/XMLSchema#string

Michael Przybylski

http://www.w3.org/2001/XMLSchema#string

Stefan Maeser

http://www.w3.org/2001/XMLSchema#string

Stephan Rawer

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

The Molecular Basis of Pharmacological Chaperoning in Human α-Galactosidase

A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder

The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.

Epitope structure of the carbohydrate recognition domain of asialoglycoprotein receptor to a monoclonal antibody revealed by high-resolution proteolytic excision mass spectrometry.

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.

Toward bioinspired galectin mimetics: identification of ligand-contacting peptides by proteolytic-excision mass spectrometry.

Surface-based and mass spectrometric approaches to deciphering sugar-protein interactions in a galactose-specific agglutinin.

Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.

Fabry disease: recent advances in enzyme replacement therapy.

P2888

s13361-016-1386-0

P304

1071-1078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13361-016-1386-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27112153

http://www.w3.org/2001/XMLSchema#string

P921

molecular chaperones